Aims: Our study aimed to describe the demographic and clinical characteristics of patients with anogenital warts investigate relationship between treatment options recurrence.
 Methods: The data who were admitted dermatology, urology, gynecology outpatient clinics 2010 2021, diagnosed retrospectively analyzed. Demographic patients, presence other sexually transmitted diseases, anatomical d...

Condyloma acuminata is caused by the proliferation of squamous epithelial cells in the presence of human papilloma virus (HPV) infection. There are several treatment options available for anogenital warts, however, none have proven to be more efficacious. We present the case of a 3 year-8 months-old male, diagnosed with human immunodeficiency virus (HIV) infection, who presented with multiple w...

In children, lesions caused by the human papillomavirus (HPV) constitute a significant epidemiological issue and a therapeutic dilemma, particularly in the case of anogenital warts. The treatment of anogenital warts in children is a challenge, since standard treatments are generally painful and require the patient to be anesthetized. Imiquimod, a topical immune response modifier, constitutes an...

BACKGROUND Although new HPV vaccines have been developed and are in the process of implementation, anogenital warts remain a very frequent problem in clinical practice. OBJECTIVE We wished to update previously published European guidelines for the management of anogenital warts. METHODS We performed a systematic review of randomized controlled trials for anogenital warts. The primary data w...

IMIQUIMOD CREAM: INDICATION Imiquimod (AldaraTM, 3M Pharmaceuticals, St. Paul, MN) is an immune-response modifier. In the United States, it is currently indicated for the treatment of external anogenital warts. Available in a 5% cream, it is applied by the patient to the warts and adjacent skin three times a week (e.g., Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday) for up to...

BACKGROUND Cellular immunity is involved in spontaneous clearance of anogenital warts caused, most typically, by human papillomavirus (HPV) type 6 or 11, supporting the concept of therapeutic vaccination. A therapeutic vaccine composed of HPV-6 L2E7 fusion protein and AS02A adjuvant was evaluated in conjunction with conventional therapies in subjects with anogenital warts. METHODS A total of ...

IMIQUIMOD CREAM: INDICATION Imiquimod (AldaraTM, 3M Pharmaceuticals, St. Paul, MN) is an immune-response modifier. In the United States, it is currently indicated for the treatment of external anogenital warts. Available in a 5% cream, it is applied by the patient to the warts and adjacent skin three times a week (e.g., Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday) for up to...

Over the past few decades, epidemiology and natural history studies have led to improved understanding of human papillomavirus (HPV) infection and to promising prevention strategies. HPV infection is the cause of anogenital warts and cervical cancer, as well as a proportion of other anogenital and head and neck cancers. Data from clinical trials have resulted in recommendations that support the...